Background: Elastosis perforans serpiginosa (EPS) is a reactive perforating dermatosis characterized by the elimination of abnormal elastic fibers from the upper dermis through the epidermis. In a few cases, it occurs as a side effect of treatment by D-penicillamine (DPA). The first case of EPS induced by DPA was described in 1972 in a patient treated for Wilson’s disease. Subsequently, cutaneous changes resembling pseudoxanthoma elasticum (PXE) were observed in patients treated with DPA and were reported as pseudo-PXE. Case Report: We report herein the clinical, pathological and ultrastructural study of 2 new cases of DPA-induced EPS and pseudo-PXE. These patients had been treated for Wilson’s disease since 14 and 16 years, respectively. Characteristic abnormal elastic fibers were found on histopathological examination of both EPS and pseudo-PXE skin and confirmed by an ultrastructural study. There was no ABCC6 mutation. Discussion: Penicillamine is able to induce widespread, cutaneous and systemic, elastic fiber damage. Our patients present typical features of DPA-induced elastosis, presenting as EPS and pseudo-PXE. ABCC6 mutation is associated with PXE and, as expected, it was absent in our cases of pseudo-PXE. This elastopathy has been related to morphologic changes in elastic fibers secondary to prolonged therapy in most cases. DPA may interfere with elastin cross-linking through inhibition of the enzyme lysyl oxidase, or by formation of complexes with the cross-linked precursors, impairing a normal maturation of elastic fibers. However, no fatal complication of DPA-induced elastopathy has been reported so far. An improvement of the cutaneous lesions is expected after the drug discontinuation.

Keywords:
Elastosis perforans, Pseudoxanthoma, Wilson’s disease, D-Penicillamine, Elastic fibers
1.
Kirsch N, Hukill PB: Elastosis perforans serpiginosa induced by penicillamine, electron microscopic observations. Arch Dermatol 1977;113:630–635.
2.
Mehta RK, Burrows NP, Rowland Payne CME, Mendelsohn SS, Pope FM, Rytina E: Elastosis perforans serpiginosa and associated disorders. Clin Exp Dermatol 2001;26:521–514.
3.
Guilaine MM, Benhamou JP, Molas G: Elastome perforant verruciforme chez un malade traité par pénicillamine pour maladie de Wilson. Bull Soc Fr Dermatol Syphiligr 1972;79:450–452.
4.
Meyrick-Thomas RH, Kirby JDT: Elastosis perforans serpiginosa and pseudo-elasticum-like skin change due to D-penicillamine. Clin Exp Dermatol 1985;10:386–391.
5.
Burge S, Ryan T: Penicillamine-induced pseudo-pseudoxanthoma elasticum in a patient with rheumatoid arthritis. Clin Exp Dermatol 1988;13:255–258.
6.
Walshe JM: Penicillamine: A new oral therapy for Wilson’s disease. Am J Med 1956;21:487.
7.
Bialy-Golan A, Brenner S: Penicillamine-induced bullous dermatoses. J Am Acad Dermatol 1996;35:732–741.
8.
Ratnavel RC, Norris PG: Penicillamine-induced elastosis perforans serpiginosa treated successfully with isotretinoin. Dermatology 1994;189:81–83.
9.
Sahn EE, Maize JC, Garen PD, Mullins SC, Silver RM: D-Penicillamine-induced elastosis perforans serpiginosa in a child with juvenile rheumatoid arthritis. J Am Acad Dermatol 1989;20:979–988.
10.
Dalziel KL, Burge SM, Frith PA, Ryan TJ, Mowat A: Elastic fibre damage induced by low-dose D-penicillamine. Br J Dermatol 1990;123:305–312.
11.
Bardach H, Gebhart W, Niebauer G: ‘Lumpy-bumpy’ elastic fibers in the skin and lungs of a patient with penicillamine-induced elastosis perforans serpiginosa. J Cutan Pathol 1979;6:243–252.
12.
Rosenblum GA: Liquid nitrogen cryotherapy in a case of elastosis perforans serpiginosa. J Am Acad Dermatol 1983;8:718–721.
13.
Le Saux O, Beck K, Sachsinger C, Silvestri C, Treiber C, Göning HH, Johnson EW, De Paepe A, Pope FM, Pasquali-Ronchetti I, Bercovitch L, Terry SF, Boyd CD: A spectrum of ABCC6 mutations responsible for pseudoxanthoma elasticum. Am J Hum Genet 2001;69:749–764.
14.
Iozumi K, Nakagawa H, Tamaki K: Penicillamine-induced degenerative dermatoses: Report of a case and brief review of such dermatoses. J Dermatol 1997;24:458–465.
15.
Bolognia B, Baverman I: Pseudoxanthoma-elasticum-like skin changes induced by penicillamine. Dermatology 1992;184:12–18.
16.
Light N, Meyrick-Thomas RH, Stephens A, Kirby JDT, Fryer PR, Avery NC: Collagen and elastin changes in D-penicillamine-induced pseudoxanthoma elasticum-like skin. Br J Dermatol 1986;114:381–388.
17.
Hashimoto K, McEvoy B, Belcher R: Ultrastructure of penicillamine-induced skin lesions. J Am Acad Dermatol 1981;4:300–315.
18.
Coatesworth AP, Darnton SJ, Green RM, Cayton RM, Antonakopoulos GN: A case of systemic pseudo-pseudoxanthoma elasticum with diverse symptomatology caused by long-term penicillin use. J Clin Pathol 1998;51:169–171.
19.
Burge S, Ryan T: Penicillamine-induced pseudo-pseudoxanthoma elasticum in a patient with rheumatoid arthritis. Clin Exp Dermatol 1988;13:255–258.
20.
Wassef M, Galian A, Pepin B, Haguenau M, Vassel P, Hautefeuille P: Unusual digestive lesions in a patient with Wilson’s disease treated with long-term penicillamine. N Engl J Med 1985;313:49.
21.
Hill VA, Seymour CA, Mortimer PS: Penicillamine-induced elastosis perforans serpiginosa and cutis laxa in Wilson’s disease. Br J Dermatol 2000;142:560–561.
22.
Deguti MM, Mucenic M, Cancado ELR: Elastosis perforans serpiginosa secondary to D-penicillamine treatment in a Wilson’s disease patient. Am J Gastroenterol 2002;97:2153–2154.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.